A Randomized Clinical Trial Evaluating Therapeutic Drug Monitoring (TDM) for Protease Inhibitor–Based Regimens in Antiretroviral-Experienced HIV-Infected Individuals: Week 48 Results of the A5146 Study

Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors

(2011) Alexandra U Scherrer et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Age-Related Changes in Plasma Concentrations of the HIV Protease Inhibitor Lopinavir

(2010) Keith W. Crawford et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients

(2009) Lisa M Demeter et al.   AIDS

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

(2009) H. Azijn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Etravirine: A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV

(2009) Daryl S. Schiller et al.   CLINICAL THERAPEUTICS

Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice

(2009) M. Fabbiani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacogenomics ofCYP3A: considerations for HIV treatment

(2009) Sukhwinder S Lakhman et al.   PHARMACOGENOMICS

Predictive Values of the Human Immunodeficiency Virus Phenotype and Genotype and of Amprenavir and Lopinavir Inhibitory Quotients in Heavily Pretreated Patients on a Ritonavir-Boosted Dual-Protease-Inhibitor Regimen

(2008) A. Barrail-Tran et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women

(2008) Matthieu Roustit et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Design and Implementation of A5146, a Prospective Trial Assessing the Utility of Therapeutic Drug Monitoring Using an Inhibitory Quotient in Antiretroviral-Experienced HIV-Infected Patients

(2008) Lisa M. Demeter et al.   HIV CLINICAL TRIALS

Antiretroviral Treatment of Adult HIV Infection

(2008) Scott M. Hammer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

(2008) Gerd Fätkenheuer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

(2008) Roy M. Gulick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

(2008) Roy T. Steigbigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of therapeutic drug monitoring in HIV disease

(2008) Matthijs van Luin et al.   Current Opinion in HIV and AIDS